Evaluation of safety and performance of CentaFlow™ in the assessment of fetal growth restriction – a randomized trial and prospective cohort study
While CF was safe to use, we found no evidence that CF can be used as a predictor of FGR. Further refinement of signal analysis is necessary to enhance CFs diagnostic utility.
Authors
- Richard Farlie (ORCID: https://orcid.org/0000-0001-5286-3244)
- Olav Bjørn Petersen (ORCID: https://orcid.org/0000-0001-8517-4082)
- Ane Lilleøre Rom (ORCID: https://orcid.org/0000-0003-2474-2677)
- Lise Hald Nielsen (ORCID: https://orcid.org/0000-0002-1859-2484)
- Mie Gaarskjær de Wolff (ORCID: https://orcid.org/0000-0002-9483-6559)
- Hanne Kristine Hegaard (ORCID: https://orcid.org/0000-0002-7093-0719)
- Anne Hammer (ORCID: https://orcid.org/0000-0002-4616-9827)
- F Sander (ORCID: https://orcid.org/0009-0004-8035-4235)
- Cathrine Vedel (ORCID: https://orcid.org/0000-0001-7475-513X)
- Dave Wright
- Sabine Hansen
Institutions
- University of Copenhagen (DK)
- University of Southern Denmark (DK)
- Aarhus University (DK)
- University of Exeter (GB)
- Hvidovre Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Regionshospitalet Viborg (DK)
- Region of Southern Denmark (DK)
- Regionshospitalet Herning (DK)
Publication Details
- Journal
- Journal of Perinatal Medicine
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1515/jpm-2025-0153
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00